Home » Stocks » MCRB

Seres Therapeutics, Inc. (MCRB)

Stock Price: $19.04 USD 0.25 (1.33%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $19.10 +0.06 (0.32%) Feb 26, 7:55 PM
Market Cap 1.74B
Revenue (ttm) 23.27M
Net Income (ttm) -89.65M
Shares Out 83.53M
EPS (ttm) -1.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $19.04
Previous Close $18.79
Change ($) 0.25
Change (%) 1.33%
Day's Open 18.93
Day's Range 17.66 - 19.62
Day's Volume 1,189,469
52-Week Range 2.52 - 38.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in two upcoming investo...

PRNewsWire - 3 days ago

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today ...

Other stocks mentioned: AXLA, CDAK, DNLI, EVLO, FHTX, KLDO, MRNA, RUBY, SANA, SGTX
Business Wire - 4 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome platform company developing a novel class of multifunctional bacterial therapeutics designed t...

Zacks Investment Research - 6 days ago

Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--New data from microbiome and metabolomic endpoints provide mechanistic support of Seres' positive Phase 3 results in recurrent C. difficile infection.

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Thu...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the publication of data analyses from the Company's Phase 1b trial of SER-287 in patients with active...

Zacks Investment Research - 2 months ago

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

Other stocks mentioned: CRSP, DNLI, NK, RCKT
The Motley Fool - 2 months ago

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

Other stocks mentioned: BNTX, CLDX, CODX, CRDF, MRNA, NSRGY, NVAX, TRIL, VXRT
The Motley Fool - 2 months ago

Investors favored coronavirus vaccine work, late-stage trial victories, and genetic sequencing.

Other stocks mentioned: INO, NVAX, PFE, TWST
Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that management will participate in two upcoming investor conferences: Piper Sandler 32nd Annual Virt...

Seeking Alpha - 3 months ago

Late August spike means share price moves from below $5 to more than $30. Capital raising and Nestle agreement raised $264 million.

Seeking Alpha - 3 months ago

Seres has seen +863% upside YTD on the back of positive top-line data in their phase 3 SER-109 study, which helps prove their microbiome hypotheses. Management have strengthened the cash posit...

Seeking Alpha - 3 months ago

Seres has appreciated over 800% in the last one year. Despite strong phase 3 efficacy data, the FDA has asked for additional safety data.

Seeking Alpha - 3 months ago

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -50.00% and -84.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB) today reported financial results from the third quarter ended September 30, 2020, and provided business updates. “Su...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has dosed the first patient in its Phase 1b trial evaluating SER-301 for the treatment of act...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome platform company developing a novel class of multifunctional bacterial therapeutics designed t...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the expansion of its leadership team with the appointments of David S. Ege, Ph.D., as Executive Vice ...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the presentation of previously announced positive Phase 3 results from the ECOSPOR III trial of SER-1...

Zacks Investment Research - 4 months ago

The tech-heavy Nasdaq index posted its best third quarter in 10 years this year.

Other stocks mentioned: AUTO, ONEQ, QQQ, QQQE, SUNW
InvestorPlace - 5 months ago

The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.

Other stocks mentioned: ADAP, CCXI, KOD, MYOV, NVAX, SRNE
Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Next Generation IBD Therapeutics Summit on...

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc.

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc.

GuruFocus - 6 months ago

A small Boston-area biotech hopes to usher in a new era in disease treatment by getting regulatory approval for its microbiome drug.

Business Wire - 6 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MCRB--Seres Therapeutics, Inc.

The Motley Fool - 6 months ago

A major investor boosted its stake in the microbiome therapeutics leader.

Investors Business Daily - 6 months ago

Seres Therapeutics stock slipped early Thursday after the small biotech priced and boosted the size of a stock offering two days after its positive drug trial news sent MCRB stock soaring. Th...

Business Wire - 6 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc.

Business Wire - 6 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc.

Investors Business Daily - 6 months ago

A Relative Strength Rating upgrade for Seres Therapeutics shows improving technical performance. The post Stocks With Rising Relative Price Strength: Seres Therapeutics appeared first on Inves...

The Motley Fool - 6 months ago

The company's new dug could be a game changer.

Benzinga - 6 months ago

Shares of the small-cap biopharma Seres Therapeutics Inc (NASDAQ: MCRB) were ripping higher Monday.

24/7 Wall Street - 6 months ago

Seres Therapeutics Inc. (NASDAQ: MCRB) shares more than tripled early on Monday after the firm announced positive late-stage results for its C.

Market Watch - 6 months ago

Shares of Seres Therapeutics Inc. MCRB, +4.74% rocketed nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapeutics company reported upbeat results...

Business Wire - 6 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MCRB--SER-109 met Phase 3 primary endpoint, showing highly statistically significant 30.2% absolute reduction in the rate of C.

Zacks Investment Research - 6 months ago

Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.

Zacks Investment Research - 7 months ago

Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Benzinga - 7 months ago

Shares of Seres Therapeutics (NASDAQ:MCRB) fell 6.4% after the company reported Q2 results.

Business Wire - 7 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MCRB--Topline data from SER-109 Phase 3 study in recurrent C.

Zacks Investment Research - 7 months ago

Seres Therapeutics (MCRB) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

Zacks Investment Research - 7 months ago

Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.

Seeking Alpha - 9 months ago

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 3.45% and 2.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 9 months ago

Seres Therapeutics: Clinical Data Coming Soon

Zacks Investment Research - 10 months ago

Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 11 months ago

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 3.85% and 11.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the ...

About MCRB

Seres Therapeutics, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in p... [Read more...]

Industry
Biotechnology
IPO Date
Jun 26, 2015
CEO
Eric Shaff
Employees
108
Stock Exchange
NASDAQ
Ticker Symbol
MCRB
Full Company Profile

Financial Performance

In 2019, MCRB's revenue was $34.51 million, an increase of 22.07% compared to the previous year's $28.27 million. Losses were -$70.28 million, -28.97% less than in 2018.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for MCRB stock is "Buy." The 12-month stock price forecast is 37.50, which is an increase of 96.95% from the latest price.

Price Target
$37.50
(96.95% upside)
Analyst Consensus: Buy